Dendritic cell-based active specific immunotherapy for malignant glioma.
Immunotherapy is an appealing therapeutic modality for malignant gliomas because of its potential to selectively target residual tumor cells that have invaded the normal brain. Most immunotherapeutic studies are designed to exploit the capacity of dendritic cells for inducing cell-mediated effects as well as immune memory responses for destroying residual tumor cells and preventing recurrence. Although initial clinical studies on dendritic cell-based immunotherapy resulted in very limited success, they have prompted many new studies on exploring strategies to induce a more robust antitumor immune response by using novel adjuvants for maturation and activation of dendritic cells. More studies have focused on the mechanisms of immune suppression by tumor cells and the role of regulatory T cells in tumor growth and progression. In this article, the authors review the evolution of dendritic cell-based immunotherapeutic strategies for adjuvant treatment of malignant gliomas. The authors also discuss how new knowledge on tumor-intrinsic mechanisms of tolerance induction and immunosuppression are likely to shape the future of immunotherapy for high-grade gliomas.
Parajuli
Prahlad
P
Wayne State University and Karmanos Cancer Institute, Department of Neurosurgery, Hudson-Webber CRC #808, 4100 John R St, Detroit, MI-48201, USA. pparajuli@med.wayne.edu
Mathupala
Saroj
S
Mittal
Sandeep
S
Sloan
Andrew E
AE
D017209:Apoptosis / Q000276:immunology* / Q000502:physiology; D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology / Q000502:physiology*; D005910:Glioma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*